Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

13G Filing: Baker Bros. Advisors and Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

Published on April 15, 2017 at 9:54 pm by Insider Monkey Staff in Hedge Funds

Page 7 of 10

Page 7 of 10 – SEC Filing

Item 2(d)

Title of Class of Securities

Common
Stock, par value $0.01 per share (“Common Stock”)

Item 2(e)

CUSIP Number

079481107

Item 3.

If this statement is filed pursuant to §§240.13d-1(b)
or (c), check whether the person filing is a:

	(a)	¨	Broker or dealer registered under Section 15 of the Exchange Act.
	(b)	¨	Bank as defined in section 3(a)(6) of the Exchange Act.
	(c)	¨	Insurance company as defined in section 3(a)(19) of the Exchange Act.
	(d)	¨	Investment company registered under section 8 of the Investment Company Act of 1940.
	(e)	x	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
	(f)	¨	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
	(g)	x	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
	(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
	(i)	¨	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.
	(j)	¨	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4.

Ownership.

Items
5 through 9 and 11 of each of the cover pages to this Schedule 13G are incorporated herein reference. Certain securities of the
Issuer are directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”), 14159, L.P. (“14159”)
and 667, L.P. (“667”, and together with Life Sciences and 14159, the “Funds”). The information set forth
below is based upon 33,078,089 shares of Common Stock outstanding as of March 31, 2017, based on information obtained from the
Issuer on April 10, 2017. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act
of 1934, as amended.

Page 7 of 10 Pages

Follow Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

Follow Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 7 of 10

NASDAQ:BLCM SEC 13G Filing Baker Bros. Advisors Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)